Now we also have biologic drugs, and one type is called TNFα blockers. These drugs mop up the excess TNFα in the body. The only one currently approved [by the FDA] for psoriatic arthritis is Enbrel* (etanercept); the other biologics, such as Remicade (infliximab) and Humira (adalimumbab), are only approved for rheumatoid arthritis, but they are also being used for psoriatic arthritis.
How effective are biologic treatments?
The big difference with these agents versus methotrexate is that these agents prevent the progression of the disease. They appear to stop the destruction in its tracks. These treatments are all extremely effective in people with joint involvement. There are, however, some differences in the way that the skin lesions respond to those different agents. Sometimes higher doses are required to get a matching improvement in the skin disease. But the joint disease improves dramatically with TNFα drugs.
What advice do you have for people with psoriasis?
I think the most important message is if you have psoriasis, then at each doctor's visit, the physician or the patient themselves need to be aware that they have approximately a one in three chance of getting the joint disease. And if a doctor is not asking, the patient has got to be telling the physician about symptoms such as, "I'm waking up with swollen joints. My hands are sore. My knees are stiff for about 30 minutes," so that they can be worked up for possible psoriatic arthritis. The sooner we treat them, the less disability there will be. At the moment, we think about one out of five patients with psoriatic arthritis will eventually be disabled. But if you start treatment early, we should be able to prevent disability in most patients.